What we saw in the fourth quarter was that Pfizer has a lot...

What we saw in the fourth quarter was that Pfizer has a lot of flexibility in terms of cost-cutting. That helped them achieve the numbers they did. But it's not like they're out of the woods. They won't be out of the woods for another two years.